New strength of Stalevo

Orion has launched a new strength of Stalevo which contains 200mg levodopa, 50mg carbidopa and 200mg entacapone.

Stalevo is indicated for the treatment of patients with Parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa carboxylase inhibitor treatment.

The additional strength has been launched to provide greater dosage flexibility to prescribers.

View Stalevo drug record

Further information: Orion

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more